SecBot SecBot
SECBOTREPLAY Home › Report › ONCY

ONCY · Oncolytics announced translational data from the GOBLET and AWARE-1…

ONCOLYTICS BIOTECH INC · 8-K filed May 22, 2026 at 09:03 ET

At the news

NEUTRALIMPACT 3/10

8-K filed May 22, 2026 at 09:03 ET

Oncolytics announced translational data from the GOBLET and AWARE-1 trials to be presented at ASCO 2026, showing pelareorep activates innate and adaptive immune responses and expands mutant KRAS-specific T cells. The press release contains no new financial information or definitive clinical outcomes, making this a routine scientific update.

  • Data will be presented at ASCO 2026 (May 29-June 2) on pelareorep's mechanism of action.
  • Translational analyses show pelareorep induces antiviral and anti-tumor immune responses.
  • Expansion of mutant KRAS-specific T cell clones correlated with tumor volume reduction in pancreatic cancer.
  • AWARE-1 breast cancer biopsies showed increased CXCL13 and tertiary lymphoid structure formation.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access